Research achievements of various countries on Maitake:
1. Improve immune regulation - American Cancer Adjuvant Therapy
2. The cancer inhibition rate of Maitake polysaccharide used in combination with chemotherapy is 98% -- Nutritional Immunology by Dr. Chen Zhaofei
3. Repair and protect the liver, and inhibit the hepatitis B virus—— Antiviral Research
4. Anti cancer effect - Professor Sun Qingji's Applied Research on Cancer Rehabilitation
5. Dermatological efficacy - Professor Sun Qingji's Academic Research on Psoriasis and Lupus Erythematosus
6. Improve hypertension, diabetes and high cholesterol - Academician Wu Qingping's Academic Research on diabetes
01 Japan -- the king of anti-cancer among the top ten medicinal fungi
In 1986, Professor Nanbo Hongzhang published a research report on "Maitake" in the Japanese Pharmaceutical Journal. The report points out that the anticancer activity of Maitake polysaccharide is stronger than some chemotherapy drugs, and there is no toxic and side effects. According to the research report "Inhibition Effect of Tricholoma (i.e. Maitake) and Other Mushrooms on Cancer", the inhibition rate of Maitake on breast cancer reached 86% to 86.6%.
02 United States - FDA made an exception to the promotion, and Maitake won the US patent
In 1998, after confirming the research results of Maitake extract in the treatment of advanced breast cancer and prostate cancer and making relevant investigations on its safety, in order to speed up its clinical promotion, the US FDA decided to allow Maitake extract, as an effective tumor inhibitor, to be exempted from the Phase I safety toxicology study and directly enter the Phase II clinical observation (IND No. 54589) to speed up its clinical promotion, It was also granted US patent protection (Patent No.: U.S. Patent 5854404). This is extremely rare in the history of FDA.
Application of Maitake, Jason, USA Dr. Staffer believes that this is like the discovery of penicillin, which will surely lead to a revolution in the history of human cancer treatment! In 2006, at the 43rd Annual Meeting of the American Society of Clinical Oncology, the experts at the meeting agreed that Maitake gave consideration to the safety and effectiveness of cancer treatment, met the new international cancer treatment norms of "making cancer treatment safer and more effective", and was worth promoting globally.
03 Canada - Maitake increases the effect of chemotherapy by 3.7 times
Dr. Kodama of Canada published an article entitled "Immunopromotion of Maitake fraction and its antagonism to mitomycin C induced immunosuppression" on Nutrition. In this article, the tumor inhibition rate of mitomycin C alone was only 18.5%, while the inhibition rate of Maitake combined with mitomycin C was 69%, 3.73 times that of single application. The research results again show that Maitake can be used alone or in combination with traditional chemotherapy drugs in clinical practice. While significantly improving the effect of cancer treatment, it can also significantly reduce the side effects of human immune suppression caused by chemotherapy drugs, thus improving the quality of life of cancer patients.
04 France - Grifola reduces cancer metastasis by 70%
The French National Institute of Health and Medical Research has proved that Maitake alone can reduce the metastasis rate of lung cancer by 70%. When combined with cisplatin, a chemotherapy drug with a dose of 3mg/KG, the metastasis rate of lung cancer is reduced by 85%, and there is no toxicity. More importantly, Maitake can reduce the nausea, vomiting, hair loss and other toxic side effects caused by cisplatin, and alleviate the pain of patients. In the mouse experiment with Lewis lung cancer as the research target, the research results show that Maitake has the strongest tumor inhibition effect, whether orally or intraperitoneally, it can significantly enhance the cellular immune activity, and it can: I) inhibit tumor growth, II) prevent tumor metastasis, III) prevent the canceration of normal cells, and IV) cooperate with radiotherapy and chemotherapy.
Article Source/Reference/quote：
http://www.xiangguwang.com.cn/shijun/content/show/id/208.html
